AstriVax Therapeutics is a European based, biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic hepatitis B (HBV) and clear high-risk human papilloma virus infection (HPV). AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that provides company the potential to develop best-in-class immunotherapy treatments.
Included in the AvH investment portfolio since 2022.
Press releases - Growth capital
View AllRelated participations
Growth Capital
Confo Therapeutics
Confo's mission is to develop novel GPCR modulators for patients with severe and underserved diseases, with a current emphasis on rare diseases, peripheral pain and obesity.
Growth Capital
DISCO Pharmaceuticals
DISCO Pharmaceuticals uses groundbreaking proteomics technology to map the cancer cell surfaceome. has pioneered the initial surfaceome mapping for Small Cell Lung Cncer (SCLC) and Colorectal Cancer (CRC). The company is currently advancing multiple ADC candidates toward studies that will enable submission for Investigational New Drug (IND) status.
Growth Capital
Vico Therapeutics
Vico Therapeutics is a Dutch biotech company developing novel Antisense-Oligonucleotide (ASO) therapies for rare diseases.